Publications 2009

1. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission. Patel B, Kirkland KE, Szydlo R, Pearce RM, Clark RE, Craddock C, Liakopoulou E, Fielding AK, Mackinnon S, Olavarria E, Potter MN, Russell NH, Shaw BE, Cook G, Goldstone AH, Marks DI. Haematologica. 2009 Oct;94(10):1399-406. doi: 10.3324/haematol.2009.008649. Epub 2009 Jul 31

2. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. Shaw BE, Veys P, Pagliuca A, Addada J, Cook G, Craddock CF, Gennery AR, Goldman J, Mackinnon S, Madrigal JA, Marks DI, Navarrete C, Potter MN, Querol S, Regan F, Russell NH, Hough RE. Bone Marrow Transplant. 2009 Jul;44(1):7-12. Epub 2009 Jan 12. Review.

3. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Malladi RK, Peniket AJ, Littlewood TJ, Towlson KE, Pearce R, Yin J, Cavenagh JD, Craddock C, Orchard KH, Olavarria E, McQuaker G, Collin M, Marks DI; British Society of Blood and Marrow Transplantation. Bone Marrow Transplant. 2009 May;43(9):709-15. doi: 10.1038/bmt.2008.375. Epub 2008 Nov 24.

4. Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based pre-emptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Lim ZY, Cook G, Johnson PR, Parker A, Zuckerman M, Marks D, Wiltshire H, Mufti GJ, Pagliuca A. Leuk Res. 2009 Feb;33(2):244-9. Epub 2008 Sep 20.